ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Elsevier Office of Continuing Medical Education (EOCME) and Excerpta Medica, Inc. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

FACULTY DISCLOSURES
As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the manufacturer(s) of any commercial product discussed during his/her presentation. The faculty of this CME activity disclose the following:

Faculty Member		Manufacturer		Relationship
Geno J. Merli, MD		AstraZeneca, The sanofi-aventis Group		Grants/Research Support, Consultant, Speaker’s Bureau
		Bacchus Vascular, Inc.		Consultant
		Bayer Pharmaceuticals Corporation		Grants/Research Support
		Bristol-Myers Squibb Company, The sanofi-aventis Group		Grants/Research Support

INFORMATION ON CME CREDIT
The EOCME designates this educational activity for a maximum of 1 category 1 credit toward the American Medical Association (AMA) Physician’s Recognition Award (PRA). Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

FINANCIAL SUPPORT
This CME activity is supported by an unrestricted educational grant from sanofi-aventis U.S.

INTENDED AUDIENCE
This activity is intended for critical care physicians, cardiologists, nephrologists, general practice and internal medicine physicians and healthcare providers who are involved with special patient populations with cardiac and renal disease who are at higher risk of thromboembolic complications.

GOAL OF THE ACTIVITY
Through completion of this activity, participants will become familiar with practical aspects related to clinical management of venous thromboembolism (VTE) and recognize how to reduce the risk of morbidity and mortality associated with VTE in patients with cardiac and renal disease.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be able to: Recognize and list risk factors for VTE List treatment options for prophylaxis of VTE Explain the role of renal insufficiency in determining a treatment regimen This activity may contain references to off-label/unapproved uses of drugs or medical devices. Please consult the product prescribing information for full disclosure of labeled uses. HARDWARE AND SOFTWARE SPECIFICATIONS NEEDED TO VIEW This course requires Windows Operating Systems (95/98, NT, 2000, ME, XP), version 5.5 browsers or higher from Microsoft or Netscape. Certain activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player. CONTENT DEVELOPMENT COMMITTEE Deepak L. Bhatt, MD Geno J. Merli, MD Mark J. Flanick, MS CME PARTICIPANT DEMOGRAPHICS Case Studies in Thromboembolic Disease: Thromboprophylaxis of a Medical Patient With Heart Failure and Renal Insufficiency, presented by Geno J. Merli, MD, Professor of Medicine, Director, Division of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. Release date: March 18, 2005 Expiration date: March 18, 2007 Estimated time to complete activity: 1 hour

     View the case study
 
     Via DSL connection >

     Via Modem connection >